News and Comments

Seres Therapeutics: A novel Approach For Treating Clostridium Difficile infection.

  Friday, August 21, 2015

but First: Here is some Good News From  More...

KITE: News we are Anxious to Hear

  Monday, August 17, 2015

Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms that are designing and developing CAR T Cell immunotherapy treatments for cancer. Many investors are wondering about the plummeting of the stock and obviously others have learned about one death that occurred during clinical trial, which caused KITE selloff.    More...

Inovio is in Much Better Shape than Six Months Ago

  Thursday, August 13, 2015

INOVIO More...

AstraZeneca Selects Mirati Therapeutics Drug For Its cancer Immunotherapy Combination

  Thursday, August 06, 2015

In The NEWS More...

NANTKWEST INC. A Novel Breathtaking Immunotherapy For Cancer?

  Monday, August 03, 2015

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day seemed confident that the stock would surge. As a matter of fact, the stock did surge.    More...

EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...

AMGN: Rapatha Approved In Europe

  Tuesday, July 21, 2015

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol More...

Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why is this Great News?

  Tuesday, July 14, 2015

An Effective Non-Steroid Atopic Dermatitis Ointment More...

Trovagine: Overcoming Challenges In Cancer Immunotherapy

  Wednesday, July 08, 2015

After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer immunotherapy), novel approaches based on new discoveries have finally demonstrated they can do the hard job. These treatments, however, are facing challenges, which must be dealt with. Will Trovagine (TROV) succeed in dealing with the challenges?  More...

Unearthing Dynavax Treasures has Nothing To Do with Greece Troubles

  Monday, June 29, 2015


Recent Postings